Satellos Bioscience (NASDAQ:MSLE) Upgraded at Canaccord Genuity Group

Satellos Bioscience (NASDAQ:MSLE) was upgraded by Canaccord Genuity Group to a “moderate buy” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

Other research analysts have also recently issued reports about the stock. Zacks Research raised shares of Satellos Bioscience to a “hold” rating in a report on Tuesday, February 10th. Cantor Fitzgerald initiated coverage on shares of Satellos Bioscience in a report on Wednesday, March 11th. They set an “overweight” rating for the company. Guggenheim initiated coverage on shares of Satellos Bioscience in a report on Tuesday, April 28th. They set a “buy” rating and a $23.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Satellos Bioscience in a report on Monday, May 11th. Finally, Leerink Partners initiated coverage on shares of Satellos Bioscience in a report on Monday, April 6th. They set an “outperform” rating and a $20.00 price target for the company. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $18.00.

Satellos Bioscience Stock Down 5.5%

Shares of NASDAQ:MSLE opened at $6.75 on Thursday. The company has a 50-day simple moving average of $7.11. Satellos Bioscience has a one year low of $4.53 and a one year high of $13.39. The stock has a market capitalization of $140.60 million, a PE ratio of -4.22 and a beta of 1.60.

Satellos Bioscience (NASDAQ:MSLE) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.02). On average, equities research analysts forecast that Satellos Bioscience will post -2.26 earnings per share for the current fiscal year.

Satellos Bioscience Company Profile

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.